[go: up one dir, main page]

MX2020006662A - Vacuna combinada intradermica contra mycoplasma y circovirus porcino. - Google Patents

Vacuna combinada intradermica contra mycoplasma y circovirus porcino.

Info

Publication number
MX2020006662A
MX2020006662A MX2020006662A MX2020006662A MX2020006662A MX 2020006662 A MX2020006662 A MX 2020006662A MX 2020006662 A MX2020006662 A MX 2020006662A MX 2020006662 A MX2020006662 A MX 2020006662A MX 2020006662 A MX2020006662 A MX 2020006662A
Authority
MX
Mexico
Prior art keywords
porcine circovirus
mycoplasma
combination vaccine
vaccine against
antigens
Prior art date
Application number
MX2020006662A
Other languages
English (en)
Inventor
Giralt Jordi Montane
Arnau Marta Sitjà
Molas Ester Puigvert
Sanz Alexandra Moros
Original Assignee
Hipra Scient S L U
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hipra Scient S L U filed Critical Hipra Scient S L U
Publication of MX2020006662A publication Critical patent/MX2020006662A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0241—Mollicutes, e.g. Mycoplasma, Erysipelothrix
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A40/00—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production
    • Y02A40/70—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production in livestock or poultry

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención proporciona una vacuna combinada que comprende uno o más antígenos de Mycoplasma hyopneumoniae, uno o más antígenos de circovirusporcino y excipientes y/o vehículos farmacéuticamente aceptables, para su uso en la prevención y/o tratamiento de la neumonía enzoótica porcina y/o enfermedades asociadas al circovirus porcino (PCVAD) mediante la administración de la vacuna en la dermis del ganado, en donde el uno o más antígenos de circovirus porcino comprende la proteína ORF2 del PCV2 en una cantidad desde 0,1 µg/dosis hasta 10 µg/dosis.
MX2020006662A 2017-12-22 2018-12-19 Vacuna combinada intradermica contra mycoplasma y circovirus porcino. MX2020006662A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17382893 2017-12-22
PCT/EP2018/085844 WO2019121916A1 (en) 2017-12-22 2018-12-19 Intradermal combination vaccine against mycoplasma and porcine circovirus

Publications (1)

Publication Number Publication Date
MX2020006662A true MX2020006662A (es) 2020-08-31

Family

ID=61024548

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020006662A MX2020006662A (es) 2017-12-22 2018-12-19 Vacuna combinada intradermica contra mycoplasma y circovirus porcino.

Country Status (7)

Country Link
US (1) US11744883B2 (es)
EP (1) EP3727432A1 (es)
JP (1) JP7510874B2 (es)
BR (1) BR112020012483A2 (es)
CA (1) CA3085535A1 (es)
MX (1) MX2020006662A (es)
WO (1) WO2019121916A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3727432A1 (en) * 2017-12-22 2020-10-28 Hipra Scientific, S.L.U. Intradermal combination vaccine against mycoplasma and porcine circovirus
CN114364398B (zh) * 2019-09-12 2025-08-22 英特维特国际股份有限公司 用于皮内施用的联合疫苗
CN112294953A (zh) * 2020-12-31 2021-02-02 北京科牧丰生物制药有限公司 一种pcv2型杆状病毒载体、猪肺炎支原体、副猪嗜血杆菌三联灭活疫苗及制备方法
WO2024235714A1 (en) * 2023-05-12 2024-11-21 Intervet International B.V. A vaccine against leptospira bacterium
CN121240875A (zh) * 2023-05-12 2025-12-30 英特维特国际股份有限公司 一种针对猪红斑丹毒丝菌和猪细小病毒的疫苗

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5565205A (en) * 1990-08-16 1996-10-15 Solvay Animal Health, Inc. Inactivated Mycoplasma hypopneumoniae bacterin and method of use thereof
BR122015028489B1 (pt) * 2005-12-29 2021-10-13 Boehringer Ingelheim Animal Health Usa Inc Vacina de combinação multivalente contra pcv2, bem como uso de uma proteína orf2 na preparação da mesma
WO2009126356A2 (en) 2008-01-23 2009-10-15 Boehringer Ingelheim Vetmedica, Inc. Pcv2 mycoplasma hyopneumoniae immunogenic compositions and methods of producing such compositions
UA114504C2 (uk) 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс Комбінована вакцина pcv, mycoplasma hyopneumoniae та prrs
US9120859B2 (en) * 2012-04-04 2015-09-01 Zoetis Services Llc Mycoplasma hyopneumoniae vaccine
EP2684959A1 (en) 2012-07-10 2014-01-15 Laboratorios Hipra, S.A. Vectors for transforming Mycoplasma hyopneumoniae, transformed M.hyopneumoniae strains, and use thereof
GB201220889D0 (en) 2012-11-21 2013-01-02 Kit Karlsrusher Inst Fuer Technologie Und Inst Fuer Toxikologie Und Genetik And Amcure Gmbh CD44v6-derived peptides for treating metastasizing cancers
ES2882374T3 (es) * 2013-05-08 2021-12-01 Pharmgate Biologics Inc Vacuna para PCV2 y micoplasma
EP3037119A1 (en) 2014-12-23 2016-06-29 Hipra Scientific, S.L.U. Device for administering medicinal products
EP3397279A1 (en) * 2015-12-28 2018-11-07 Merial, Inc. M hyo multivalent vaccine and uses thereof
CN108697782A (zh) 2016-03-23 2018-10-23 英特维特国际股份有限公司 针对pcv2病毒和猪肺炎支原体感染的组合疫苗
EP3727432A1 (en) * 2017-12-22 2020-10-28 Hipra Scientific, S.L.U. Intradermal combination vaccine against mycoplasma and porcine circovirus

Also Published As

Publication number Publication date
US20200376106A1 (en) 2020-12-03
JP2021506874A (ja) 2021-02-22
BR112020012483A2 (pt) 2020-11-24
JP7510874B2 (ja) 2024-07-04
US11744883B2 (en) 2023-09-05
WO2019121916A1 (en) 2019-06-27
CA3085535A1 (en) 2019-06-27
EP3727432A1 (en) 2020-10-28

Similar Documents

Publication Publication Date Title
MX2020006662A (es) Vacuna combinada intradermica contra mycoplasma y circovirus porcino.
MX393855B (es) Terapia de combinación que comprende un inhibidor de raf y trametinib
WO2018136412A3 (en) Subcutaneous her2 antibody formulations
PH12021550479A1 (en) Dengue vaccine unit dose and administration thereof
UA124347C2 (uk) Циклічна динуклеотидна сполука
JOP20220092A1 (ar) جسم مضاد لبيتا-النشواني لعلاج مرض الزهايمر
MX392525B (es) Composiciones inmunogenicas para su uso en vacunas neumococicas
NZ759686A (en) Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
CA3030422C (en) Stabilizing excipients for therapeutic protein formulations
MX2021014948A (es) Metodos de tratamiento de pacientes con una composicion inmunogenica que protege contra el seroripo 29 de s. pneumoniae.
AR090885A1 (es) Uso de laquinimod en alta dosis para el tratamiento de la esclerosis multiple
BR112018069100A2 (pt) uma vacina combinada contra a infecção por vírus pcv2 e mycoplasma hyopneumoniae
ZA202107428B (en) Porcine circovirus type 3 (pcv3) vaccines, and production and uses thereof
UY32208A (es) Uso de antigeno de mycoplasma bovis
MX2020008454A (es) Composicion inmunogenica que comprende antigenos estafilococicos.
MX2022003090A (es) Vacuna combinada para ser administrable intradermicamente.
MX2015016750A (es) Composicion inmunogenica para uso en terapia.
BR112018014723A2 (pt) fantasmas bacterianos para o tratamento de câncer
MX2021005421A (es) Macrólidos de 13 miembros con sustitución cíclica en c10 y usos de los mismos.
BR112016012435A8 (pt) vacina, e, usos de uma proteína orf2 recombinantemente expressada do circovírus porcino tipo 2
MY191905A (en) M hyo multivalent vaccine and uses thereof
MX2021005423A (es) Macrolidos de 13 miembros sustituidos con c10-alquileno y usos de los mismos.
EP4335455A3 (en) Vaccines containing swine pathogens for associated non-mixed use
MX2020013484A (es) Vacunacion contra circovirus porcinos.
RU2018137033A (ru) Вакцина для внутрикожного применения против инфекции вируса pcv2 и prrs